Original ArticleA multicenter evaluation of oral pressure therapy for the treatment of obstructive sleep apnea
Introduction
Obstructive sleep apnea (OSA) is a common medical condition [1], [2] which causes substantial morbidity and possibly mortality [3]. The process of repetitive airflow obstruction during sleep and the consequent need to arouse to breathe precipitates a reduction in the restorative effect of sleep, often leading to daytime sleepiness [4]. OSA patients also are at a significantly increased risk for negative impact on measures of attention and vigilance and on mood disturbance [5]. Moreover, chronic untreated OSA yields a significantly increased risk for cardiovascular diseases over a period of years, including hypertension, cardiac arrhythmias, atherosclerotic heart disease, myocardial infarction, stroke, death [6], and possibly type 2 diabetes mellitus [7].
No treatment exists for OSA that is both completely effective and fully tolerated by all patients; many partially efficacious or partially tolerated treatments currently are in use. Although nasal continuous positive airway pressure (CPAP) is the recommended therapy for reducing apneas and hypopneas [8], adherence to CPAP often is low [9], [10]. Given the seriousness of the risks associated with untreated or ineffectively treated OSA, it is important for physicians and patients to have a wide variety of treatment options to increase the likelihood of a successful option [11]. Our study describes a novel treatment modality, oral pressure therapy (OPT), which applies a vacuum to the mouth to stabilize upper airway tissue in patients with OSA.
Section snippets
Methods
The ATLAST study was a 4-week, multicenter, prospective, open-label, randomized, crossover, first-night order of control vs treatment, single-arm trial of the Winx Sleep Therapy System for the treatment of OSA. The objective of the study was to evaluate safety and efficacy of the Winx Sleep Therapy System. The study was approved by Western Institutional Review Board, Olympia, Washington, was conducted in compliance with US Food and Drug Administration Good Clinical Practice guidelines, and was
Subject disposition
Subject disposition is summarized in Fig. 2. The analysis cohort of 63 subjects comprised 33% without prior OSA treatment, 24% with prior CPAP experience who had abandoned CPAP therapy, and 43% who were active CPAP users when they elected to participate in our study.
AHI and ODI
Across the whole analysis cohort, the AHI reduction was statistically significant compared to controls at the first treatment night (Wilcoxon signed rank, P < .0001) and the treatment night following day 28 (Wilcoxon signed rank, P =
Discussion
Data from the analysis cohort of 63 subjects indicated that OPT led to statistically significant improvements in AHI and ODI on the first treatment night and following 28 days of use. In the same cohort, there were statistically significant alterations in sleep architecture on treatment nights with reduced stage 1 shifts, reduced awakenings, a smaller arousal index, and reduced time spent in stage 1 sleep on both treatment nights relative to baseline; increased sleep efficiency, decreased wake
Conflicts of interest
Dr Black is a consultant to ApniCure and Dr Siegel is employed by ApniCure.
Acknowledgment
This work was supported by ApniCure Inc.
References (30)
- et al.
Obstructive sleep apnea and depression
Sleep Med Rev
(2009) - et al.
Treatment adherence and outcomes in flexible vs standard continuous positive airway pressure therapy
Chest
(2005) - et al.
CPAP and behavioral therapies in patients with obstructive sleep apnea: effects on daytime sleepiness, mood, and cognitive function
Sleep Med Rev
(2009) - et al.
A convenient expiratory positive airway pressure nasal device for the treatment of sleep apnea in patients non-adherent with continuous positive airway pressure
Sleep Med
(2011) - et al.
Epidemiology and natural history of obstructive sleep apnea
Ear Nose Throat J
(1993) - et al.
Epidemiology of obstructive sleep apnea: a population health perspective
Am J Respir Crit Care Med
(2002) - et al.
Sleep-disordered breathing and mortality: a prospective cohort study
PLoS Med
(2009) - et al.
Sleep apnea syndrome due to upper airway obstruction: a review of 25 cases
Arch Intern Med
(1977) - et al.
Role of obstructive sleep apnea in cardiovascular disease
Curr Opin Cardiol
(2011) - et al.
Obstructive sleep apnea and type 2 diabetes: is there a link?
Front Neurol
(2012)
Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders
Sleep
A pilot study assessing adherence to auto-bilevel following a poor initial encounter with CPAP
J Clin Sleep Med
Practice parameters for the medical therapy of obstructive sleep apnea
Sleep
Adherence to continuous positive airway pressure therapy: the challenge to effective treatment
Proc Am Thorac Soc
Mechanism of action of a novel device using oral pressure therapy (OPT) for the treatment of OSA
Am J Respir Crit Care Med
Cited by (49)
The Food and Drug Administration's (FDA's) 510(k) Process: A Systematic Review of 1000 Cases
2023, American Journal of MedicinePhysiology and dynamics of the pharyngeal airway
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second Edition[Translated article] International consensus document on obstructive sleep apnea
2022, Archivos de BronconeumologiaConsidering the Role of Adherence in New and Emerging Sleep Treatments
2021, Sleep Medicine ClinicsBuilding a model to precisely target the responders of a novel intermittent negative air pressure device-with mechanism definition
2020, Sleep MedicineCitation Excerpt :However, due to the complexity and diversity of OSAS, engaging patients in effective and “compatible” treatment is always a challenge. Over the past few years, oral pressure therapy (OPT) has emerged and has been proven to be an effective alternative treatment for continuous positive airway pressure (CPAP)-incompliant patients, with the treatment response rate varying largely between 25% and 79% [13–17], depending on the respiratory events rating rules and criteria used to define the “responders” to certain treatment. The latest OPT system, an intermittent negative airway pressure (iNAP) device [16,17], has a significantly lower oral tissue discomfort rate than the predicate device.